Viewing Study NCT02220894


Ignite Creation Date: 2025-12-25 @ 1:32 AM
Ignite Modification Date: 2026-03-09 @ 8:12 AM
Study NCT ID: NCT02220894
Status: COMPLETED
Last Update Posted: 2023-10-10
First Post: 2014-08-19
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PD-1 View
None PD1 View
None PD-L1 View
None PDL1 View